Immune-modified exosome vaccine loaded with liver cancer epitope peptides induces potent and specific antitumor immunity
DEX<sub>AGNP</sub> is a modular exosome vaccine that combines epitope-specific antigen presentation with immune activation and PD-L1 blockade, enabling robust antitumor T-cell responses across complementary liver cancer models. This engineered DEX platform provides a practical blueprint for developing next-generation exosome-based cancer vaccines.
Institutions
- Capital Medical University (CN)
- Affiliated Hospital of Chengde Medical College (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Beijing YouAn Hospital (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-03-24
- DOI
- https://doi.org/10.1186/s12951-026-04166-y
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00